Seth Bannon
@sethbannon.bsky.social
Entrepreneur. Investor. Happy warrior. Founder Fifty Years. ❤️ climate, bio, deeptech. Helping build civilizationally important companies.
None of those are reasons we need to test in animals. They're reasons we needed to test in animals. We're on the cusp of having better modeling and non-animal systems to get this data.
April 11, 2025 at 3:11 AM
None of those are reasons we need to test in animals. They're reasons we needed to test in animals. We're on the cusp of having better modeling and non-animal systems to get this data.
9/ We’re entering an era where the slowest part of medicine won’t be the science -- it’ll be the willingness of institutions to evolve.
Good to see the FDA modernizing like this!
Good to see the FDA modernizing like this!
April 10, 2025 at 9:26 PM
9/ We’re entering an era where the slowest part of medicine won’t be the science -- it’ll be the willingness of institutions to evolve.
Good to see the FDA modernizing like this!
Good to see the FDA modernizing like this!
8/ The old dogma: “We have to test it in animals.”
The new ethos: “We should test it in systems that work.”
That means leveraging AI, synthetic biology, and human-relevant models.
The new ethos: “We should test it in systems that work.”
That means leveraging AI, synthetic biology, and human-relevant models.
April 10, 2025 at 9:26 PM
8/ The old dogma: “We have to test it in animals.”
The new ethos: “We should test it in systems that work.”
That means leveraging AI, synthetic biology, and human-relevant models.
The new ethos: “We should test it in systems that work.”
That means leveraging AI, synthetic biology, and human-relevant models.
7/ The downstream effect?
💊 Cheaper drugs
🐭 Fewer animals used
⚡️ Faster approvals
🧠 More accurate models of human biology
💊 Cheaper drugs
🐭 Fewer animals used
⚡️ Faster approvals
🧠 More accurate models of human biology
April 10, 2025 at 9:26 PM
7/ The downstream effect?
💊 Cheaper drugs
🐭 Fewer animals used
⚡️ Faster approvals
🧠 More accurate models of human biology
💊 Cheaper drugs
🐭 Fewer animals used
⚡️ Faster approvals
🧠 More accurate models of human biology
6/ This isn’t just a policy update. It’s a signal.
The regulatory state is catching up to the science.
And that opens the door to faster, safer, and more ethical drug development.
The regulatory state is catching up to the science.
And that opens the door to faster, safer, and more ethical drug development.
April 10, 2025 at 9:26 PM
6/ This isn’t just a policy update. It’s a signal.
The regulatory state is catching up to the science.
And that opens the door to faster, safer, and more ethical drug development.
The regulatory state is catching up to the science.
And that opens the door to faster, safer, and more ethical drug development.
5/ The FDA just released new draft guidance:
🧪 Removing routine animal tests for mAbs targeting non-human antigens
🧠 Encouraging case-by-case waivers for other biologics
👀 Eyeing “stepwise” expansion of non-animal approaches
🧪 Removing routine animal tests for mAbs targeting non-human antigens
🧠 Encouraging case-by-case waivers for other biologics
👀 Eyeing “stepwise” expansion of non-animal approaches
April 10, 2025 at 9:26 PM
5/ The FDA just released new draft guidance:
🧪 Removing routine animal tests for mAbs targeting non-human antigens
🧠 Encouraging case-by-case waivers for other biologics
👀 Eyeing “stepwise” expansion of non-animal approaches
🧪 Removing routine animal tests for mAbs targeting non-human antigens
🧠 Encouraging case-by-case waivers for other biologics
👀 Eyeing “stepwise” expansion of non-animal approaches
4/ The focus now is monoclonal antibodies (mAbs), the engine behind many of the most important therapies in cancer, autoimmune disease, and infectious disease.
April 10, 2025 at 9:26 PM
4/ The focus now is monoclonal antibodies (mAbs), the engine behind many of the most important therapies in cancer, autoimmune disease, and infectious disease.